Xintela Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Xintela
Access all reports
Xintela AB is a Sweden-based biomedical company specializing in regenerative medicine and cancer treatments. The company focuses on developing therapies for cartilage damage and osteoarthritis using its proprietary XINMARK technology, which identifies specific stem cells that can develop into cartilage cells. In oncology, Xintela is working on targeted treatments for aggressive cancers, including glioblastoma. Through its subsidiary Targinta, the company also develops antibody-based therapies targeting cancer cells. The company is headquartered in Lund, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Ticker symbol
XINT
Country
đžđȘ Sweden